HRP20190805T1 - Spojevi triazolopirimidina i njihova uporaba - Google Patents
Spojevi triazolopirimidina i njihova uporaba Download PDFInfo
- Publication number
- HRP20190805T1 HRP20190805T1 HRP20190805TT HRP20190805T HRP20190805T1 HR P20190805 T1 HRP20190805 T1 HR P20190805T1 HR P20190805T T HRP20190805T T HR P20190805TT HR P20190805 T HRP20190805 T HR P20190805T HR P20190805 T1 HRP20190805 T1 HR P20190805T1
- Authority
- HR
- Croatia
- Prior art keywords
- alkyl
- independently selected
- compound
- pharmaceutically acceptable
- acceptable salt
- Prior art date
Links
- YWBFPKPWMSWWEA-UHFFFAOYSA-O triazolopyrimidine Chemical class BrC1=CC=CC(C=2N=C3N=CN[N+]3=C(NCC=3C=CN=CC=3)C=2)=C1 YWBFPKPWMSWWEA-UHFFFAOYSA-O 0.000 title 1
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 37
- 150000001875 compounds Chemical class 0.000 claims 32
- 150000003839 salts Chemical class 0.000 claims 24
- 229910052736 halogen Inorganic materials 0.000 claims 9
- 150000002367 halogens Chemical class 0.000 claims 9
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 6
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 6
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims 5
- 125000004432 carbon atom Chemical group C* 0.000 claims 5
- 125000005842 heteroatom Chemical group 0.000 claims 5
- 125000004767 (C1-C4) haloalkoxy group Chemical group 0.000 claims 4
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- 125000001072 heteroaryl group Chemical group 0.000 claims 4
- 229910052739 hydrogen Inorganic materials 0.000 claims 4
- 229910052760 oxygen Inorganic materials 0.000 claims 4
- 229940124597 therapeutic agent Drugs 0.000 claims 4
- 239000000825 pharmaceutical preparation Substances 0.000 claims 3
- JNCMHMUGTWEVOZ-UHFFFAOYSA-N F[CH]F Chemical compound F[CH]F JNCMHMUGTWEVOZ-UHFFFAOYSA-N 0.000 claims 2
- 108010081348 HRT1 protein Hairy Proteins 0.000 claims 2
- 102100021881 Hairy/enhancer-of-split related with YRPW motif protein 1 Human genes 0.000 claims 2
- 230000003474 anti-emetic effect Effects 0.000 claims 2
- 239000000043 antiallergic agent Substances 0.000 claims 2
- 229940125683 antiemetic agent Drugs 0.000 claims 2
- 239000002111 antiemetic agent Substances 0.000 claims 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 230000001120 cytoprotective effect Effects 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- VUWZPRWSIVNGKG-UHFFFAOYSA-N fluoromethane Chemical compound F[CH2] VUWZPRWSIVNGKG-UHFFFAOYSA-N 0.000 claims 2
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 2
- 239000002955 immunomodulating agent Substances 0.000 claims 2
- 229940121354 immunomodulator Drugs 0.000 claims 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 2
- 229940127084 other anti-cancer agent Drugs 0.000 claims 2
- 229940124641 pain reliever Drugs 0.000 claims 2
- 238000002560 therapeutic procedure Methods 0.000 claims 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 2
- 125000004737 (C1-C6) haloalkoxy group Chemical group 0.000 claims 1
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims 1
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims 1
- 125000006163 5-membered heteroaryl group Chemical group 0.000 claims 1
- 206010003571 Astrocytoma Diseases 0.000 claims 1
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 208000003174 Brain Neoplasms Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 206010014733 Endometrial cancer Diseases 0.000 claims 1
- 206010014759 Endometrial neoplasm Diseases 0.000 claims 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 1
- 208000022072 Gallbladder Neoplasms Diseases 0.000 claims 1
- 208000032612 Glial tumor Diseases 0.000 claims 1
- 206010018338 Glioma Diseases 0.000 claims 1
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 206010027406 Mesothelioma Diseases 0.000 claims 1
- 208000034578 Multiple myelomas Diseases 0.000 claims 1
- 208000001894 Nasopharyngeal Neoplasms Diseases 0.000 claims 1
- 206010061306 Nasopharyngeal cancer Diseases 0.000 claims 1
- 206010029260 Neuroblastoma Diseases 0.000 claims 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010033963 Parathyroid tumour Diseases 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 208000015634 Rectal Neoplasms Diseases 0.000 claims 1
- 208000006265 Renal cell carcinoma Diseases 0.000 claims 1
- 208000008938 Rhabdoid tumor Diseases 0.000 claims 1
- 101100465401 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) SCL1 gene Proteins 0.000 claims 1
- 206010039491 Sarcoma Diseases 0.000 claims 1
- 208000021712 Soft tissue sarcoma Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 210000003445 biliary tract Anatomy 0.000 claims 1
- 201000009036 biliary tract cancer Diseases 0.000 claims 1
- 208000020790 biliary tract neoplasm Diseases 0.000 claims 1
- 229910052799 carbon Inorganic materials 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 1
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 claims 1
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 201000004101 esophageal cancer Diseases 0.000 claims 1
- 201000003444 follicular lymphoma Diseases 0.000 claims 1
- 201000010175 gallbladder cancer Diseases 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 208000005017 glioblastoma Diseases 0.000 claims 1
- 201000010536 head and neck cancer Diseases 0.000 claims 1
- 208000014829 head and neck neoplasm Diseases 0.000 claims 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims 1
- 125000000623 heterocyclic group Chemical group 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 208000007538 neurilemmoma Diseases 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 125000003373 pyrazinyl group Chemical group 0.000 claims 1
- 125000002098 pyridazinyl group Chemical group 0.000 claims 1
- 125000004076 pyridyl group Chemical group 0.000 claims 1
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 1
- 206010038038 rectal cancer Diseases 0.000 claims 1
- 201000001275 rectum cancer Diseases 0.000 claims 1
- 208000015347 renal cell adenocarcinoma Diseases 0.000 claims 1
- 206010039667 schwannoma Diseases 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 201000002510 thyroid cancer Diseases 0.000 claims 1
- 208000017997 tumor of parathyroid gland Diseases 0.000 claims 1
- 208000025421 tumor of uterus Diseases 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
- 206010046766 uterine cancer Diseases 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Claims (27)
1. Spoj, naznačen time, što je predstavljen Formulom (I):
ili njegova farmaceutski prihvatljiva sol, u kojoj:
je jednostruka veza ili dvostruka veza;
R1 i R2 su neovisno H ili halogen;
R3 je neovisno odabran od: halogena, fenila i 5-članog do 6-članog heteroarila koji obuhvaća ugljikove atome i 1-4 heteroatoma koji su odabrani od N, NRa, O i S(O)p; pri čemu su navedeni fenil i heteroaril supstituirani s 0-3 R3A;
svaki R3A je neovisno odabran od: halogena, CN, -(O)m-(C1-C6 alkila supstituiranog s 0-1 R3B), C1-C6 haloalkila, C1-C6 haloalkoksi, R3C, -OR3C, -C(=O)R3D, NR3ER3F,
-C(=O)NR3ER3F, -NHC(=O)R3D, -S(=O)2R3D, -S(=O)2NR3ER3F,
-NHS(=O)2(C1-C4 alkil) i -CR3CR3ER3G;
R3B je neovisno odabran od: OH, NReRf, C1-C4 alkoksi, -C(=O)NReRf,
-S(=O)2(C1-C4 alkil), -NHC(=O)(C1-C4 alkil), i 5-članog do 6-članog heterocikloalkila koji obuhvaća ugljikove atome i 1-2 heteroatoma koji su odabrani od N, NRa, O, i S(O)p; pri čemu je navedeni heterocikloalkil supstituiran s 0-2 RC;
svaki R3C je neovisno odabran od: C3-C6 cikloalkila, fenila, i 4-članog do 7-članog heterocikla koji obuhvaća ugljikove atome i 1-4 heteroatoma koji su odabrani od N, NRa, O, i S(O)p; pri čemu je svaki dio skupine supstituiran s 0-2 Rc;
svaki R3D je neovisno odabran od: C1-C4 alkil i R3C;
R3E i R3G su, pri svakoj pojavi, neovisno odabrani od: H i C1-C4 alkila;
svaki R3F je neovisno odabran od: H i C1-C4 alkila supstituiranog s 0-1 Rd;
R4 je neovisno odabran od: H, halogena i C1-C4 alkila;
R5 je neovisno odabran od OH i C1-C4 alkila;
svaki Ra je neovisno odabran od: H, →O, C1-C4 alkila supstituiranog s 0-1 Rb,
-C(=O)H, -C(=O)(C1-C4 alkila), -CO2(C1-C4 alkila), C3-C6 cikloalkila, i benzila;
Rb je neovisno odabran od: halogena, OH i C1-C4 alkoksi;
[0001] svaki Rc je neovisno odabran od: =O, halogena, OH, C1-C4 alkila, C1-C4 haloalkila, C1-C4 alkoksi, i C1-C4 haloalkoksi;
Rd je neovisno odabran od: OH i NReRf;
Re i Rf su, pri svakoj pojavi, neovisno odabrani od: H i C1-C4 alkila;
svaki p je neovisno odabran od 0, 1 i 2; i
m i n su, pri svakoj pojavi, neovisno odabrani od 0 i 1.
2. Spoj ili njegova farmaceutski prihvatljiva sol, prema zahtjevu 1, naznačen time, što:
[0002] svaki R3A je neovisno odabran od: halogena, CN, -(O)m-(C1-C4 alkila supstituiranog s 0-1 R3B), C1-C4 haloalkila, C1-C4 haloalkoksi, R3C, -C(=O)R3D, NR3ER3F,
[0003] -C(=O)NR3ER3F, -S(=O)2R3D, -S(=O)2NHR3F, -NHS(=O)2(C1-C4 alkil),
[0004] -O-C3-C6 cikloalkila, i
[0005] ;
Ra je neovisno odabran od: H, →O, C1-C4 alkila supstituiranog s 0-1 Rb, -C(=O)H,
-C(=O)(C1-C4 alkila), -CO2(C1-C4 alkila), i C3-C6 cikloalkila;
R4 je H;
m je neovisno odabran od 0 i 1; i
n je 0.
3. Spoj ili njegova farmaceutski prihvatljiva sol, prema zahtjevu 1 ili zahtjevu 2, naznačen time, što:
R1 je neovisno H ili F;
R2 je H; i
R3 je neovisno odabran od: fenila, i 6-članog heteroarila koji obuhvaća ugljikove atome i 1-2 heteroatoma koji su odabrani od N i NRa; pri čemu su navedeni fenil i heteroaril supstituirani s 0-3 R3A.
4. Spoj ili njegova farmaceutski prihvatljiva sol, prema bilo kojem od zahtjeva 1 do 3, naznačen time, što:
R3 je neovisno odabran od: fenila, piridila, pirimidila, piridazinila i pirazinila; pri čemu je svaki dio skupine supstituiran s 0-3 R3A.
5. Spoj ili njegova farmaceutski prihvatljiva sol, prema bilo kojem od zahtjeva 1 do 4, naznačen time, što:
R3 je neovisno odabran od:
i
.
6. Spoj ili njegova farmaceutski prihvatljiva sol, prema bilo kojem od zahtjeva 1 do 4, naznačen time, što:
R3 je neovisno odabran od:
i
[0006] ;
svaki R3A je neovisno odabran od: halogena, CN, -(O)m-(C1-C4 alkila supstituiranog s 0-1 R3B), C1-C4 haloalkila, C1-C4 haloalkoksi, -C(=O)NH2, -C(=O)NH(C1-C4 alkila),
-C(=O)N(C1-C4alkila)2, -C(=O)N(C1-C4alkil)(CH2)2N(C1-C4 alkila)2,
-CH2NHC(=O)(C1-C4 alkila), -S(=O)2R3D, -S(=O)2NH(C1-C4 alkila supstituiranog s 0-1 OH), -NHS(=O)2(C1-C4 alkila), NH2, -NH(C1-C4 alkila), -N(C1-C4 alkila)2,
C3-C6 cikloalkila,
i
[0007] ;
R3B je neovisno odabran od: OH, NH2, NH(C1-C4 alkila), N(C1-C4 alkila)2,
C1-C4 alkoksi, -C(=O)N(C1-C4 alkila)2, -S(=O)2(C1-C4 alkila),
i
;
R3D je neovisno odabran od: C1-C4 alkila i 1H-piperidin-4-ila; i
svaki Ra je neovisno odabran od: H, C1-C4 alkila, -C(=O)H, -C(=O)(C1-C4 alkila), i
-CO2(C1-C4 alkila).
7. Spoj ili njegova farmaceutski prihvatljiva sol, prema bilo kojem od zahtjeva 1 do 6, naznačen time, što:
R3 je neovisno odabran od:
i
;
svaki R3A je neovisno odabran od: halogena, CN, -(O)m-(C1-C4 alkila supstituiranog s 0-1 R3B), C1-C4 haloalkila, C1-C4 haloalkoksi, -C(=O)NH2, -C(=O)NH(C1-C4 alkila),
-C(=O)N(C1-C4alkila)2, -C(=O)N(C1-C4 alkil)(CH2)2N(C1-C4 alkila)2,
-CH2NHC(=O)(C1-C4alkila), -S(=O)2(C1-C4alkila), NH2, NH(C1-C4 alkila),
N(C1-C4 alkila)2, C3-C6 cikloalkila,
i
;
[0008] R3B je neovisno odabran od: OH, N(C1-C4 alkila)2, C1-C4 alkoksi,
[0009] -C(=O)N(C1-C4 alkila)2, -S(=O)2(C1-C4 alkila),
i
; i
svaki Ra je neovisno odabran od: H, C1-C4 alkila, -C(=O)H, -C(=O)(C1-C4 alkila), i
-CO2(C1-C4 alkila).
8. Spoj ili njegova farmaceutski prihvatljiva sol, prema bilo kojem od zahtjeva 1 do 7, naznačen time, što:
svaki R3A je neovisno odabran od: F, Cl, CH3, -CH2OH, CH2F, CHF2, CF3, CN,
-OCH3, -OCH2CH3, -OCH(CH3)2, -OCHF2, -C(=O)N(CH3)2, -CH2NHC(=O)CH3,
-S(=O)2CH3, NH2, ciklopropila,
i
[0010] .
9. Spoj ili njegova farmaceutski prihvatljiva sol, prema bilo kojem od zahtjeva 1 do 8, naznačen time, što je navedeni spoj predstavljen Formulom (IA-1):
ili njegova farmaceutski prihvatljiva sol, gdje:
R1 je neovisno H ili F; i
R3A je neovisno odabran od: F, CH3, -CH2OH, CH2F, CHF2, CF3, i -OCH3.
10. Spoj prema zahtjevu 1 ili zahtjevu 2, naznačen time, što:
R1 je neovisno H ili F;
R2 je H;
R3 je neovisno 5-člani heteroaril koji obuhvaća ugljikove atome i 1-4 heteroatoma koji su odabrani od N, NRa, O, i S(O)p; pri čemu je navedeni heteroaril supstituiran s 0-3 R3A; i
Ra je neovisno odabran od: H, C1-C4 alkila supstituiranog s 0-1 Rb, -C(=O)H,
-C(=O)(C1-C4 alkila), -CO2(C1-C4 alkila), C3-C6 cikloalkila, i benzila.
11. Spoj ili njegova farmaceutski prihvatljiva sol, prema bilo kojem od zahtjeva 1, 2 ili 10, naznačen time, što:
R3 je neovisno odabran od:
,
,
,
, i
.
12. Spoj ili njegova farmaceutski prihvatljiva sol, prema bilo kojem od zahtjeva 1 do 11, naznačen time, što:
R1 je F.
13. Spoj ili njegova farmaceutski prihvatljiva sol, prema zahtjevu 1, naznačen time, što je navedeni spoj odabran iz niza koji čine:
14. Spoj prema zahtjevu 1, naznačen time, što navedeni spoj je:
[0011] ,
ili njegova farmaceutski prihvatljiva sol.
15. Spoj prema zahtjevu 1, naznačen time, što navedeni spoj je:
[0012] ,
ili njegova farmaceutski prihvatljiva sol.
16. Spoj prema zahtjevu 1, naznačen time, što navedeni spoj je:
[0013] ,
ili njegova farmaceutski prihvatljiva sol.
17. Spoj prema zahtjevu 1, naznačen time, što navedeni spoj je:
[0014] ,
ili njegova farmaceutski prihvatljiva sol.
18. Spoj prema zahtjevu 1, naznačen time, što navedeni spoj je:
[0015] ,
ili njegova farmaceutski prihvatljiva sol.
19. Spoj prema zahtjevu 1, naznačen time, što navedeni spoj je:
[0016] ,
ili njegova farmaceutski prihvatljiva sol.
20. Farmaceutski pripravak, naznačen time, što obuhvaća jedan ili više farmaceutski prihvatljivih nosača i spoj ili njegovu farmaceutski prihvatljivu sol, prema bilo kojem od zahtjeva 1 do 19.
21. Farmaceutski pripravak prema zahtjevu 20, naznačen time, što nadalje obuhvaća najmanje jedno dodatno terapijsko sredstvo.
22. Farmaceutski pripravak prema zahtjevu 21, naznačen time, što je navedeno dodatno terapijsko sredstvo odabrano od drugih antikancerogenih sredstava, imunomodulatora, antialergijskih sredstava, antiemetika, sredstava za ublažavanje boli, citozaštitnih sredstava, i njihovih kombinacija.
23. Spoj ili njegova farmaceutski prihvatljiva sol, prema bilo kojem od zahtjeva 1 do 19, naznačen time, što je za uporabu u terapiji.
24. Spoj ili njegova farmaceutski prihvatljiva sol, prema bilo kojem od zahtjeva 1 do 19, za uporabu kao što je navedeno u patentnom zahtjevu 23, naznačen time, što je navedena terapija liječenje bolesti ili poremećaja posredovanog s EED i/ili PRC2.
25. Spoj ili njegova farmaceutski prihvatljiva sol, prema bilo kojem od zahtjeva 1 do 19, za uporabu kao što je navedeno u patentnom zahtjevu 24, naznačen time, što je navedena bolest odabrana ili je poremećaj odabran od difuznog limfoma velikih B-stanica, folikularnog limfoma, drugih limfoma, leukemije, multiplog mijeloma, mezotelioma, raka želuca, malignog rabdoidnog tumora, hepatocelularnog karcinoma, raka prostate, karcinoma dojke, karcinoma žučnih puteva i žučnog mjehura, karcinoma mjehura, tumora mozga uključujući neuroblastom, schwannom, gliom, glioblastom i astrocitom, raka grlića maternice, raka debelog crijeva, melanoma, raka endometrija, raka jednjaka, raka glave i vrata, raka pluća, nazofaringealnog karcinoma, raka jajnika, raka gušterače, karcinoma bubrežnih stanica, rektalnog raka, karcinoma štitnjače, paratiroidnih tumora, tumora maternice, sarkoma mekog tkiva.
26. Kombinacija, naznačena time, što se tvori od spoja ili njegove farmaceutski prihvatljive soli, prema bilo kojem od zahtjeva 1 do 19, i najmanje jednog dodatnog terapijskog sredstva.
27. Kombinacija prema zahtjevu 26, naznačena time, što je dodatno terapijsko sredstvo odabrano od drugih antikancerogenih sredstava, imunomodulatora, antialergijskih sredstava, antiemetika, sredstava za ublažavanje boli, citozaštitnih sredstava, i njihovih kombinacija.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2014094644 | 2014-12-23 | ||
CN2015095320 | 2015-11-23 | ||
PCT/IB2015/059843 WO2016103155A1 (en) | 2014-12-23 | 2015-12-21 | Triazolopyrimidine compounds and uses thereof |
EP15820637.5A EP3237418B1 (en) | 2014-12-23 | 2015-12-21 | Triazolopyrimidine compounds and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20190805T1 true HRP20190805T1 (hr) | 2019-06-28 |
Family
ID=55071101
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20190805TT HRP20190805T1 (hr) | 2014-12-23 | 2019-04-29 | Spojevi triazolopirimidina i njihova uporaba |
Country Status (40)
Country | Link |
---|---|
US (5) | US10220036B2 (hr) |
EP (1) | EP3237418B1 (hr) |
JP (1) | JP6736559B2 (hr) |
KR (1) | KR102534028B1 (hr) |
CN (1) | CN107108637B (hr) |
AU (1) | AU2015370524B2 (hr) |
BR (1) | BR112017010354B8 (hr) |
CA (1) | CA2969090C (hr) |
CL (1) | CL2017001572A1 (hr) |
CO (1) | CO2017005992A2 (hr) |
CR (1) | CR20170285A (hr) |
CY (1) | CY1121901T1 (hr) |
DK (1) | DK3237418T3 (hr) |
DO (1) | DOP2017000149A (hr) |
EA (1) | EA032416B1 (hr) |
EC (1) | ECSP17047153A (hr) |
ES (1) | ES2722048T3 (hr) |
GT (1) | GT201700146A (hr) |
HR (1) | HRP20190805T1 (hr) |
HU (1) | HUE043060T2 (hr) |
IL (1) | IL252135B (hr) |
JO (1) | JO3489B1 (hr) |
LT (1) | LT3237418T (hr) |
ME (1) | ME03385B (hr) |
MX (1) | MX2017008529A (hr) |
MY (1) | MY186837A (hr) |
NZ (1) | NZ731664A (hr) |
PE (1) | PE20171307A1 (hr) |
PH (1) | PH12017501016A1 (hr) |
PL (1) | PL3237418T3 (hr) |
PT (1) | PT3237418T (hr) |
RS (1) | RS58679B1 (hr) |
SG (1) | SG11201703880VA (hr) |
SI (1) | SI3237418T1 (hr) |
SV (1) | SV2017005472A (hr) |
TN (1) | TN2017000204A1 (hr) |
TW (1) | TWI694076B (hr) |
UA (1) | UA120945C2 (hr) |
UY (1) | UY36462A (hr) |
WO (1) | WO2016103155A1 (hr) |
Families Citing this family (43)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2722048T3 (es) * | 2014-12-23 | 2019-08-07 | Novartis Ag | Compuestos de triazolopirimidina y usos de los mismos |
EP3464643A4 (en) * | 2016-06-01 | 2020-04-01 | Epizyme Inc | USE OF EZH2 INHIBITORS FOR THE TREATMENT OF CANCER |
IL263429B (en) * | 2016-06-20 | 2022-08-01 | Novartis Ag | Crystalline forms of a triazolopyrimidine compound |
EP3472161B1 (en) * | 2016-06-20 | 2020-03-25 | Novartis AG | Triazolopyridine compounds and uses thereof |
CN109790166A (zh) * | 2016-06-20 | 2019-05-21 | 诺华股份有限公司 | 咪唑并吡啶化合物用于治疗癌症 |
TWI806832B (zh) | 2016-07-12 | 2023-07-01 | 美商銳新醫藥公司 | 作為異位shp2抑制劑之2,5-雙取代型3-甲基吡嗪及2,5,6-三取代型3-甲基吡嗪 |
CN106831601A (zh) * | 2017-01-13 | 2017-06-13 | 河北博伦特药业有限公司 | 一种2‑氨基甲基嘧啶盐酸盐及其衍生物的合成方法 |
BR112019014527A2 (pt) | 2017-01-23 | 2020-02-27 | Revolution Medicines, Inc. | Compostos de piridina como inibidores de shp2 alostéricos |
EP3571199A1 (en) | 2017-01-23 | 2019-11-27 | Revolution Medicines, Inc. | Bicyclic compounds as allosteric shp2 inhibitors |
WO2018170290A1 (en) * | 2017-03-15 | 2018-09-20 | Fulcrum Therapeutics, Inc. | Compositions and methods for increasing fmr1 expression |
US10266542B2 (en) | 2017-03-15 | 2019-04-23 | Mirati Therapeutics, Inc. | EZH2 inhibitors |
BR112019017108A2 (pt) * | 2017-03-16 | 2020-04-07 | Jiangsu Hengrui Medicine Co | derivados de heteroaril[4,3-c]pirimidina-5-amina, método de preparação dos mesmos, e usos médicos dos mesmos |
CN110944628A (zh) | 2017-06-02 | 2020-03-31 | Epizyme股份有限公司 | 使用ezh2抑制剂治疗癌症 |
CN109575013A (zh) | 2017-09-28 | 2019-04-05 | 中国科学院上海药物研究所 | 三氮唑并嘧啶、三氮唑并吡啶化合物及其组合物用于治疗prc2介导的疾病 |
WO2019062435A1 (zh) * | 2017-09-28 | 2019-04-04 | 中国科学院上海药物研究所 | 三氮唑并嘧啶、三氮唑并吡啶化合物及其组合物用于治疗prc2介导的疾病 |
RU2020115095A (ru) | 2017-10-12 | 2021-11-12 | Революшн Медсинз, Инк. | Пиридиновые, пиразиновые и триазиновые соединения в качестве аллостерических ингибиторов shp2 |
CN109867645B (zh) * | 2017-12-05 | 2021-09-14 | 中国医学科学院药物研究所 | 一种2,2-二氟-2,3-二氢取代苯并呋喃类化合物的合成方法 |
KR20200099530A (ko) * | 2017-12-15 | 2020-08-24 | 레볼루션 메디슨즈, 인크. | 알로스테릭 shp2 억제제로서의 다환식 화합물 |
CN109942556A (zh) * | 2017-12-21 | 2019-06-28 | 上海青煜医药科技有限公司 | 嘧啶酮化合物及其应用 |
EP3743416B1 (en) | 2018-01-23 | 2023-03-15 | Basf Se | Halogenation of pyridine derivatives |
DK3746446T3 (da) * | 2018-01-31 | 2022-06-27 | Mirati Therapeutics Inc | PRC2-inhibitorer |
CN110156787B (zh) * | 2018-02-13 | 2021-11-02 | 中国科学院上海药物研究所 | 一种三氮唑并嘧啶衍生化合物、包含其的药物组合物及其用途 |
CN110563722A (zh) * | 2018-06-06 | 2019-12-13 | 上海青煜医药科技有限公司 | 吡啶或哒嗪并环化合物及其应用 |
CN110734436A (zh) * | 2018-07-19 | 2020-01-31 | 上海青煜医药科技有限公司 | 嘧啶或吡嗪并环化合物及其应用 |
MX2021006026A (es) * | 2018-11-30 | 2021-07-06 | Tuojie Biotech Shanghai Co Ltd | Pirimidina y derivado heterociclico de nitrogeno de cinco miembros, metodo de preparacion y usos medicos de los mismos. |
CN111518100A (zh) * | 2019-02-02 | 2020-08-11 | 上海青煜医药科技有限公司 | 环丙烯并苯并呋喃取代的氮杂芳基化合物及其应用 |
MX2021011118A (es) * | 2019-03-15 | 2022-01-18 | Fulcrum Therapeutics Inc | Derivados de azolopiridina macrocíclicos como moduladores de eed y prc2. |
JP7299307B2 (ja) * | 2019-04-03 | 2023-06-27 | テラ・ストーン株式会社 | チミン核酸塩基をベースとするトリアゾロピリミジン類及びその製造方法 |
US20220213097A1 (en) * | 2019-04-22 | 2022-07-07 | Mirati Therapeutics, Inc. | Naphthyridine derivatives as prc2 inhibitors |
CN113874377A (zh) | 2019-05-13 | 2021-12-31 | 埃科莱布美国股份有限公司 | 作为铜腐蚀抑制剂的1,2,4-三唑并[1,5-a]嘧啶衍生物 |
CA3142477A1 (en) * | 2019-06-05 | 2020-12-10 | Athenex, Inc. | Methods of treating and/or preventing psoriasis |
EP3980422A1 (en) * | 2019-06-05 | 2022-04-13 | Mirati Therapeutics, Inc. | Imidazo[1,2-c]pyrimidine derivatives as prc2 inhibitors for treating cancer |
CN112409385B (zh) * | 2019-08-22 | 2024-08-13 | 上海青煜医药科技有限公司 | 氮杂芳基化合物及其应用 |
CA3150284A1 (en) * | 2019-09-26 | 2021-04-01 | Novartis Ag | Aza-quinoline compounds and uses thereof |
EP4056570A4 (en) * | 2019-11-01 | 2023-12-20 | ShanghaiTech University | EED INHIBITOR AND PRODUCTION METHOD AND USE THEREOF |
CN113004233B (zh) * | 2019-12-18 | 2022-12-20 | 南京优氟医药科技有限公司 | 一种用于制备prc2抑制剂的化合物、其制备方法和用途 |
CN111333655B (zh) * | 2020-04-13 | 2021-07-13 | 武汉工程大学 | 一种三唑并嘧啶类化合物及其制备方法和应用 |
EP4149932A4 (en) * | 2020-05-11 | 2024-06-26 | Ascentage Pharma (Suzhou) Co., Ltd. | PROCESS FOR PREPARING (5-FLUOR-2, 3-DIHYDROBENZOFURAN-4-YL) METHANAMINE OR ITS SALT AND INTERMEDIATE PRODUCTS THEREOF |
CA3185154A1 (en) | 2020-05-28 | 2021-12-02 | Novartis Ag | Dosing regimens for n-((5-fluoro-2,3-dihydrobenzofuran-4-yl)methyl)-8-(2-methylpyridin-3-yl)-[1,2,4]triazolo[4,3-c]pyrimidin-5-amine, or a pharmaceutically acceptable salt thereof, for use in treating prc2-mediated diseases or disorders |
CN114907385A (zh) | 2021-02-10 | 2022-08-16 | 上海青煜医药科技有限公司 | 氮杂芳基化合物、其制备方法及应用 |
TW202312995A (zh) * | 2021-08-11 | 2023-04-01 | 大陸商上海青煜醫藥科技有限公司 | 氮雜芳基化合物、其製備方法及應用 |
CN117384153A (zh) * | 2022-07-12 | 2024-01-12 | 上海赛岚生物科技有限公司 | 一类甲基转移酶抑制剂及其用途 |
WO2024215699A1 (en) * | 2023-04-11 | 2024-10-17 | Oric Pharmaceuticals, Inc. | Treatment of t-cell lymphoma |
Family Cites Families (50)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2779780A (en) | 1955-03-01 | 1957-01-29 | Du Pont | 1, 4-diamino-2, 3-dicyano-1, 4-bis (substituted mercapto) butadienes and their preparation |
EP0647450A1 (en) | 1993-09-09 | 1995-04-12 | BEHRINGWERKE Aktiengesellschaft | Improved prodrugs for enzyme mediated activation |
WO2000035436A2 (en) | 1998-12-16 | 2000-06-22 | Warner-Lambert Company | Treatment of arthritis with mek inhibitors |
NL1014106C2 (nl) | 2000-01-18 | 2001-07-20 | Univ Amsterdam | Werkwijze voor het detecteren van een pathologische afwijking bij een cel, een antistof en een assay kit. |
AU2001273498B2 (en) | 2000-07-19 | 2006-08-24 | Warner-Lambert Company | Oxygenated esters of 4-iodo phenylamino benzhydroxamic acids |
SE519662C2 (sv) | 2001-07-04 | 2003-03-25 | Asept Int Ab | Ventilanordning vid utportioneringsanordningar |
AU2002357667A1 (en) * | 2001-10-24 | 2003-05-06 | Iconix Pharmaceuticals, Inc. | Modulators of phosphoinositide 3-kinase |
US6921762B2 (en) | 2001-11-16 | 2005-07-26 | Amgen Inc. | Substituted indolizine-like compounds and methods of use |
AU2003224672B2 (en) | 2002-03-08 | 2010-02-04 | Eisai R&D Management Co., Ltd. | Macrocyclic compounds useful as pharmaceuticals |
ES2335276T3 (es) | 2002-03-13 | 2010-03-24 | Array Biopharma, Inc. | Derivados de bencimidazol alquilado n3 como inhibidores de mek. |
GB0228900D0 (en) | 2002-12-11 | 2003-01-15 | Ml Lab Plc | Cancer Immunotherapy |
JP2004238296A (ja) * | 2003-02-04 | 2004-08-26 | Kissei Pharmaceut Co Ltd | 新規なトリアゾロピリミジン誘導体、それを含有する医薬組成物およびそれらの用途 |
JP2007524596A (ja) | 2003-02-28 | 2007-08-30 | トランスフォーム・ファーマシューティカルズ・インコーポレイテッド | 共結晶医薬組成物 |
JP2007516693A (ja) | 2003-06-09 | 2007-06-28 | ザ・リージェンツ・オブ・ザ・ユニバーシティ・オブ・ミシガン | 癌の治療および診断のための組成物および方法 |
US20060246505A1 (en) | 2003-09-02 | 2006-11-02 | Reinhard Walther | Modulation of the synthesis of insulin |
WO2005118796A2 (en) | 2004-06-01 | 2005-12-15 | The University Of North Carolina At Chapel Hill | Reconstituted histone methyltransferase complex and methods of identifying modulators thereof |
GB0510390D0 (en) | 2005-05-20 | 2005-06-29 | Novartis Ag | Organic compounds |
US7452892B2 (en) | 2005-06-17 | 2008-11-18 | Bristol-Myers Squibb Company | Triazolopyrimidine cannabinoid receptor 1 antagonists |
CA2618218C (en) | 2005-07-21 | 2015-06-30 | Ardea Biosciences, Inc. | N-(arylamino)-sulfonamide inhibitors of mek |
JO2660B1 (en) | 2006-01-20 | 2012-06-17 | نوفارتيس ايه جي | Pi-3 inhibitors and methods of use |
US7890267B2 (en) | 2006-03-31 | 2011-02-15 | Ordway Research Institute | Prognostic and diagnostic method for cancer therapy |
WO2008083251A2 (en) | 2006-12-27 | 2008-07-10 | Usc Stevens - University Of Southern California | Dna methylation markers based on epigenetic stem cell signatures in cancer |
WO2009017670A2 (en) | 2007-07-26 | 2009-02-05 | University Of Massachusetts | Ras-mediated epigenetic silencing effectors and uses thereof |
EP2183255A4 (en) | 2007-08-29 | 2011-06-15 | Methylgene Inc | METHOD AND INTERMEDIATE PRODUCTS FOR THE PREPARATION OF CONDENSED HETEROCYCLIC KINASE INHIBITORS |
CN101939006B (zh) | 2007-09-12 | 2015-09-16 | 吉宁特有限公司 | 磷酸肌醇3-激酶抑制剂化合物与化疗剂的联合以及使用方法 |
JP5348725B2 (ja) | 2007-10-25 | 2013-11-20 | ジェネンテック, インコーポレイテッド | チエノピリミジン化合物の製造方法 |
US8168784B2 (en) | 2008-06-20 | 2012-05-01 | Abbott Laboratories | Processes to make apoptosis promoters |
GB0822248D0 (en) | 2008-12-05 | 2009-01-14 | Medical Res Council | Crystal meths |
US8895526B2 (en) | 2009-03-27 | 2014-11-25 | Cold Spring Harbor Laboratory | Identification of RNAI targets and use of RNAI for rational therapy of chemotherapy-resistant leukemia and other cancers |
CN102020643A (zh) * | 2009-09-22 | 2011-04-20 | 上海恒瑞医药有限公司 | 二氢喋啶酮类衍生物、其制备方法及其在医药上的应用 |
TW201200518A (en) | 2010-03-10 | 2012-01-01 | Kalypsys Inc | Heterocyclic inhibitors of histamine receptors for the treatment of disease |
UA110112C2 (uk) * | 2010-05-07 | 2015-11-25 | Глаксосмітклайн Ллс | Індоли |
CA3176977A1 (en) | 2010-09-10 | 2012-03-15 | Epizyme, Inc. | Inhibitors of human ezh2, and methods of use thereof |
WO2012151277A1 (en) | 2011-05-02 | 2012-11-08 | Applied Informatic Solutions, Inc. | Kits and methods for selecting a treatment for ovarian cancer |
US20140213475A1 (en) | 2011-07-14 | 2014-07-31 | University Of Massachusetts | Methods of diagnosing cancer using epigenetic biomarkers |
KR20140082742A (ko) | 2011-09-30 | 2014-07-02 | 글락소스미스클라인 엘엘씨 | 암을 치료하는 방법 |
CA2867282C (en) | 2012-03-12 | 2024-04-02 | Epizyme, Inc. | Inhibitors of human ezh2, and methods of use thereof |
US20150291598A1 (en) | 2012-11-19 | 2015-10-15 | Novartis Ag | Compounds and compositions for the treatment of parasitic diseases |
WO2014100080A1 (en) | 2012-12-19 | 2014-06-26 | Glaxosmithkline Llc | Combination |
WO2014124326A1 (en) | 2013-02-08 | 2014-08-14 | Stem Centrx, Inc. | Novel multispecific constructs |
TWI629273B (zh) | 2013-02-11 | 2018-07-11 | 美商星宿藥物公司 | 甲基修飾酵素之調節劑、其組成物及用途 |
JP2016516046A (ja) | 2013-03-14 | 2016-06-02 | ジェネンテック, インコーポレイテッド | がんの治療方法及びがん薬物耐性を阻止する方法 |
WO2014151142A1 (en) | 2013-03-15 | 2014-09-25 | Constellation Pharmaceuticals, Inc. | Modulators of methyl modifying enzymes, compositions and uses thereof |
EP2970306A4 (en) | 2013-03-15 | 2016-08-03 | Epizyme Inc | SUBSTITUTED BICYCLIC HETEROARYL COMPOUNDS CONDENSED IN 6.5 |
EP3104706B1 (en) | 2014-02-11 | 2022-03-23 | Mitokinin, Inc. | Compositions and methods using the same for treatment of neurodegenerative and mitochondrial disease |
PL3218329T3 (pl) | 2014-11-14 | 2019-09-30 | Basf Se | Etery benzylowo-propargilowe jako inhibitory nitrifikacji |
ES2668688T3 (es) | 2014-12-16 | 2018-05-21 | Omya International Ag | Carbonato de calcio para protección vegetal |
MA41272A (fr) | 2014-12-23 | 2017-10-31 | Adama Makhteshim Ltd | 5-fluoro-4-imino-3-(alkyle/alkyle substitué)-1-(arylsulfonyl)-3,4-dihydropyrimidin-2(1h)-one en tant que traitement des semences |
ES2722048T3 (es) * | 2014-12-23 | 2019-08-07 | Novartis Ag | Compuestos de triazolopirimidina y usos de los mismos |
GB201501017D0 (en) | 2014-12-23 | 2015-03-04 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (HCC) and other cancers |
-
2015
- 2015-12-21 ES ES15820637T patent/ES2722048T3/es active Active
- 2015-12-21 NZ NZ731664A patent/NZ731664A/en unknown
- 2015-12-21 PL PL15820637T patent/PL3237418T3/pl unknown
- 2015-12-21 CA CA2969090A patent/CA2969090C/en active Active
- 2015-12-21 UA UAA201704770A patent/UA120945C2/uk unknown
- 2015-12-21 KR KR1020177016880A patent/KR102534028B1/ko active IP Right Grant
- 2015-12-21 US US15/538,348 patent/US10220036B2/en active Active
- 2015-12-21 UY UY0001036462A patent/UY36462A/es not_active Application Discontinuation
- 2015-12-21 LT LTEP15820637.5T patent/LT3237418T/lt unknown
- 2015-12-21 ME MEP-2019-127A patent/ME03385B/me unknown
- 2015-12-21 SG SG11201703880VA patent/SG11201703880VA/en unknown
- 2015-12-21 EA EA201791420A patent/EA032416B1/ru not_active IP Right Cessation
- 2015-12-21 CN CN201580070691.5A patent/CN107108637B/zh active Active
- 2015-12-21 MY MYPI2017701623A patent/MY186837A/en unknown
- 2015-12-21 DK DK15820637.5T patent/DK3237418T3/da active
- 2015-12-21 AU AU2015370524A patent/AU2015370524B2/en active Active
- 2015-12-21 CR CR20170285A patent/CR20170285A/es unknown
- 2015-12-21 PE PE2017001154A patent/PE20171307A1/es unknown
- 2015-12-21 PT PT15820637T patent/PT3237418T/pt unknown
- 2015-12-21 SI SI201530725T patent/SI3237418T1/sl unknown
- 2015-12-21 JP JP2017533767A patent/JP6736559B2/ja active Active
- 2015-12-21 WO PCT/IB2015/059843 patent/WO2016103155A1/en active Application Filing
- 2015-12-21 EP EP15820637.5A patent/EP3237418B1/en active Active
- 2015-12-21 HU HUE15820637A patent/HUE043060T2/hu unknown
- 2015-12-21 BR BR112017010354A patent/BR112017010354B8/pt active IP Right Grant
- 2015-12-21 US US14/977,273 patent/US9580437B2/en active Active
- 2015-12-21 TN TN2017000204A patent/TN2017000204A1/en unknown
- 2015-12-21 RS RS20190502A patent/RS58679B1/sr unknown
- 2015-12-21 MX MX2017008529A patent/MX2017008529A/es active IP Right Grant
- 2015-12-22 JO JOP/2015/0331A patent/JO3489B1/ar active
- 2015-12-22 TW TW104143216A patent/TWI694076B/zh active
-
2017
- 2017-05-07 IL IL252135A patent/IL252135B/en active IP Right Grant
- 2017-06-01 PH PH12017501016A patent/PH12017501016A1/en unknown
- 2017-06-16 CL CL2017001572A patent/CL2017001572A1/es unknown
- 2017-06-16 CO CONC2017/0005992A patent/CO2017005992A2/es unknown
- 2017-06-21 DO DO2017000149A patent/DOP2017000149A/es unknown
- 2017-06-23 SV SV2017005472A patent/SV2017005472A/es unknown
- 2017-06-23 GT GT201700146A patent/GT201700146A/es unknown
- 2017-07-20 EC ECIEPI201747153A patent/ECSP17047153A/es unknown
-
2019
- 2019-01-11 US US16/246,380 patent/US20190142837A1/en not_active Abandoned
- 2019-04-29 HR HRP20190805TT patent/HRP20190805T1/hr unknown
- 2019-04-30 CY CY20191100456T patent/CY1121901T1/el unknown
-
2020
- 2020-04-30 US US16/863,631 patent/US11207325B2/en active Active
-
2021
- 2021-10-19 US US17/505,271 patent/US11931363B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20190805T1 (hr) | Spojevi triazolopirimidina i njihova uporaba | |
HRP20191826T4 (hr) | Derivati n-piridinil acetamida kao inhibitori wnt signalnog puta | |
TN2015000102A1 (en) | Bis(fluoroalkyl)-1,4-benzodiazepinone compounds as notch inhibitors | |
PH12017502246A1 (en) | New hydroxyester derivatives, a process for their preparation and pharmaceutical compositions containing them | |
NZ626942A (en) | New indolizine derivatives, method for preparing same and pharmaceutical compositions containing same | |
HRP20220864T1 (hr) | Derivati n-piridinil acetamida kao inhibitori signalnog puta wnt | |
NZ630205A (en) | Enhancer of zeste homolog 2 inhibitors | |
HRP20220886T1 (hr) | Pripravci i postupci za proizvodnju pirimidina i spojeva piridina s btk inhibicijskom aktivnošću | |
PH12015501517A1 (en) | Pyrimidone derivatives and their use in the treatment, amelioration or prevention of a viral disease | |
RU2015154275A (ru) | Комбинации антитела против pd-l1 и ингибитора mek и/или ингибитора braf | |
HRP20170736T1 (hr) | Indoli | |
JP2016512520A5 (hr) | ||
MX2016001011A (es) | Derivados de quinazolin-4-ona sustituida. | |
GEP201606532B (en) | Benzamide derivatives for inhibiting the activity of abl1, abl2 and bcr-abl1 | |
SA515360469B1 (ar) | مركبات حلقية غير متجانسة لتثبيط إنزيم جلوتاميناز والطرق الخاصة باستخدامها | |
PH12014502788A1 (en) | ARYL SULTAM DERIVATIVES AS RORc MODULATORS | |
MX2014014106A (es) | Derivados de acido 7-oxo-tiazolopiridinocarbonico y su uso en el tratamiento, disminucion o prevencion de una enfermedad viral. | |
NZ723772A (en) | Neprilysin inhibitors | |
DOP2012000153A (es) | Derivados de sulfonamida como agentes inductores de apoptosis con selectividad por bcl-2 para el tratamiento de cancer y enfermedades inmunes | |
MX338887B (es) | Alcoxipirazoles como activadores de guanilato ciclasa soluble. | |
MX2014002208A (es) | Inhibidores de serina/treonina quinasa. | |
AR066078A1 (es) | Derivados de tetrahidroindol y tetrahidroindazol. procesos de obtencion, composiciones farmaceuticos y usos. | |
MX2014000783A (es) | Compuestos de piridazinona y su uso como inhibidores de la enzima d-aminoacido oxidasa (daao). | |
HRP20210158T1 (hr) | Postupak i sustav za premještanje fluida iz posude za opskrbu u komponentu za isporuku | |
MX2015008288A (es) | Derivados de piridona y su uso en el tratamiento, mejora o prevencion de una enfermedad viral. |